Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature

Alissa Groenendijk; Filippo Spreafico; Ronald R de Krijger; Jarno Drost; Jesper Brok; Daniela Perotti; Harm van Tinteren; Rajkumar Venkatramani; Jan Godziński; Christian Rübe; James I Geller; Norbert Graf; Marry M van den Heuvel-Eibrink; Annelies M C Mavinkurve-Groothuis

doi:10.3390/cancers13133142

Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature

Alissa Groenendijk, Filippo Spreafico, Ronald R de Krijger, Jarno Drost, Jesper Brok, Daniela Perotti, Harm van Tinteren, Rajkumar Venkatramani, Jan Godziński, Christian Rübe, James I Geller, Norbert Graf, Marry M van den Heuvel-Eibrink, Annelies M C Mavinkurve-Groothuis

Research output: Contribution to journal › Article › peer-review

34 Citations (Scopus)

Abstract

In high-income countries, the overall survival of children with Wilms tumors (WT) is ~90%. However, overall, 15% of patients experience tumor recurrence. The adverse prognostic factors currently used for risk stratification (advanced stage, high risk histology, and combined loss of heterozygosity at 1p and 16q in chemotherapy-naïve WTs) are present in only one third of these cases, and the significance of these factors is prone to change with advancing knowledge and improved treatment regimens. Therefore, we present a comprehensive, updated overview of the published prognostic variables for WT recurrence, ranging from patient-, tumor- and treatment-related characteristics to geographic and socioeconomic factors. Improved first-line treatment regimens based on clinicopathological characteristics and advancing knowledge on copy number variations unveil the importance of further investigating the significance of biological markers for WT recurrence in international collaborations.

Original language	English
Article number	3142
Journal	Cancers
Volume	13
Issue number	13
DOIs	https://doi.org/10.3390/cancers13133142
Publication status	Published - 23 Jun 2021

Keywords

Pediatric
Prognosis
Recurrence
Wilms tumor

Access to Document

10.3390/cancers13133142

Cite this

Groenendijk, A., Spreafico, F., de Krijger, R. R., Drost, J., Brok, J., Perotti, D., van Tinteren, H., Venkatramani, R., Godziński, J., Rübe, C., Geller, J. I., Graf, N., van den Heuvel-Eibrink, M. M., & Mavinkurve-Groothuis, A. M. C. (2021). Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature. Cancers, 13(13), Article 3142. https://doi.org/10.3390/cancers13133142

@article{aa57c6133fa044ca9d92fc6573e2c563,

title = "Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature",

abstract = "In high-income countries, the overall survival of children with Wilms tumors (WT) is ~90%. However, overall, 15% of patients experience tumor recurrence. The adverse prognostic factors currently used for risk stratification (advanced stage, high risk histology, and combined loss of heterozygosity at 1p and 16q in chemotherapy-na{\"i}ve WTs) are present in only one third of these cases, and the significance of these factors is prone to change with advancing knowledge and improved treatment regimens. Therefore, we present a comprehensive, updated overview of the published prognostic variables for WT recurrence, ranging from patient-, tumor- and treatment-related characteristics to geographic and socioeconomic factors. Improved first-line treatment regimens based on clinicopathological characteristics and advancing knowledge on copy number variations unveil the importance of further investigating the significance of biological markers for WT recurrence in international collaborations.",

keywords = "Pediatric, Prognosis, Recurrence, Wilms tumor",

author = "Alissa Groenendijk and Filippo Spreafico and {de Krijger}, {Ronald R} and Jarno Drost and Jesper Brok and Daniela Perotti and {van Tinteren}, Harm and Rajkumar Venkatramani and Jan Godzi{\'n}ski and Christian R{\"u}be and Geller, {James I} and Norbert Graf and {van den Heuvel-Eibrink}, {Marry M} and Mavinkurve-Groothuis, {Annelies M C}",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = jun,

day = "23",

doi = "10.3390/cancers13133142",

language = "English",

volume = "13",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "13",

}

TY - JOUR

T1 - Prognostic Factors for Wilms Tumor Recurrence

T2 - A Review of the Literature

AU - Groenendijk, Alissa

AU - Spreafico, Filippo

AU - de Krijger, Ronald R

AU - Drost, Jarno

AU - Brok, Jesper

AU - Perotti, Daniela

AU - van Tinteren, Harm

AU - Venkatramani, Rajkumar

AU - Godziński, Jan

AU - Rübe, Christian

AU - Geller, James I

AU - Graf, Norbert

AU - van den Heuvel-Eibrink, Marry M

AU - Mavinkurve-Groothuis, Annelies M C

PY - 2021/6/23

Y1 - 2021/6/23

N2 - In high-income countries, the overall survival of children with Wilms tumors (WT) is ~90%. However, overall, 15% of patients experience tumor recurrence. The adverse prognostic factors currently used for risk stratification (advanced stage, high risk histology, and combined loss of heterozygosity at 1p and 16q in chemotherapy-naïve WTs) are present in only one third of these cases, and the significance of these factors is prone to change with advancing knowledge and improved treatment regimens. Therefore, we present a comprehensive, updated overview of the published prognostic variables for WT recurrence, ranging from patient-, tumor- and treatment-related characteristics to geographic and socioeconomic factors. Improved first-line treatment regimens based on clinicopathological characteristics and advancing knowledge on copy number variations unveil the importance of further investigating the significance of biological markers for WT recurrence in international collaborations.

AB - In high-income countries, the overall survival of children with Wilms tumors (WT) is ~90%. However, overall, 15% of patients experience tumor recurrence. The adverse prognostic factors currently used for risk stratification (advanced stage, high risk histology, and combined loss of heterozygosity at 1p and 16q in chemotherapy-naïve WTs) are present in only one third of these cases, and the significance of these factors is prone to change with advancing knowledge and improved treatment regimens. Therefore, we present a comprehensive, updated overview of the published prognostic variables for WT recurrence, ranging from patient-, tumor- and treatment-related characteristics to geographic and socioeconomic factors. Improved first-line treatment regimens based on clinicopathological characteristics and advancing knowledge on copy number variations unveil the importance of further investigating the significance of biological markers for WT recurrence in international collaborations.

KW - Pediatric

KW - Prognosis

KW - Recurrence

KW - Wilms tumor

UR - http://www.scopus.com/inward/record.url?scp=85108278393&partnerID=8YFLogxK

U2 - 10.3390/cancers13133142

DO - 10.3390/cancers13133142

M3 - Article

C2 - 34201787

SN - 2072-6694

VL - 13

JO - Cancers

JF - Cancers

IS - 13

M1 - 3142

ER -

Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature

Abstract

Keywords

Access to Document

Fingerprint

Cite this